Results 1 to 2 of 2

Thread: Vasogen's VP025 Delays Disease Onset and Prolongs Survival in Preclinical ALS (Lou Gehrig's disease) Model

  1. #1
    Senior Member Max's Avatar
    Join Date
    Jul 2001
    Location
    Montreal,Province of Quebec, CANADA
    Posts
    15,036

    Vasogen's VP025 Delays Disease Onset and Prolongs Survival in Preclinical ALS (Lou Gehrig's disease) Model

    Vasogen's VP025 Delays Disease Onset and Prolongs Survival in Preclinical ALS (Lou Gehrig's disease) Model
    Monday October 4, 9:08 am ET
    Research Presented at the 128th Annual Meeting of the American Neurological Association


    TORONTO, Oct. 4 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN - News; TSX:VAS - News), a research and development company focused on immune modulation therapies targeting the chronic inflammation underlying cardiovascular and neurological disorders, today announced the presentation of preclinical research demonstrating the ability of VP025 to significantly delay the onset of disease and increase survival in a model of amyotrophic lateral sclerosis (ALS) -- also referred to as Lou Gehrig's disease. This research, presented today at the 128th Annual Meeting of the American Neurological Association in Toronto by Dr. David Beers, was conducted under the direction of Dr. Stan Appel, Chief of Neurology at the Methodist Hospital, Professor of Neurology at Baylor College of Medicine, and member of Vasogen's Scientific Advisory Board.

    http://biz.yahoo.com/prnews/041004/to122_1.html

  2. #2
    Senior Member golanbenoni's Avatar
    Join Date
    Aug 2004
    Location
    Brooklyn, NY, U.S.A.
    Posts
    215
    Thanks for posting this. I will be in touch with them in the next day or so to see if I can find out anymore information.

    asogen - Developing Therapies Targeting Inflammation

    Vasogen is a leader in the research and commercial development of immune modulation therapies targeting the chronic inflammation underlying cardiovascular disorders. Inflammation is a normal response of the immune system to cellular injury caused by infection, trauma, or other stimuli. During the inflammatory process, immune cells are attracted to the site of inflammation where they release cytokines - potent chemical messengers that control inflammation and facilitate the healing process. While inflammation is normally self-limiting, it can persist and become chronic. Recent advances in medical research have established the fundamental role of chronic inflammation in the development and progression of a number of serious conditions, including heart failure, atherosclerosis, and neurodegenerative diseases.

    Our lead product, Celacadeâ„¢ (immune modulation therapy), is in phase III clinical development for the treatment of chronic heart failure and peripheral arterial disease. We are also developing a new class of phospholipid-based drugs designed to interact with antigen presenting cells (APCs) to regulate cytokine levels and control inflammation. VP025, the lead product candidate from this new class of drugs, has been optimized for the treatment of neurological disorders.
    Golan.

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •